Citi analyst Andrew Baum raised the firm’s price target on Eli Lilly to $895 from $675 and keeps a Buy rating on the shares. The analyst cites increased anticipated risk-adjusted peak sales for Eli Lilly’s oral small molecule GLP-1 agonist orforglipron as a mono/fixed dose combination for the target increase. The risk of drug-related hepato-toxicity is diminishing with both Phase III trials have been enrolling patients since 2023, the analyst tells investors in a research note. The firm says that with peak incretin sales estimates for Lilly over $85B, it is “ever more sensitized” to competitive risks to Lilly and Novo’s dominance. It anticipates unconstrained volumes of generic semaglutide in China in the mid-term and in western markets post 2032. It believes Lilly and Novo retain sufficient competitive advantages to preserve their dominant market position and grow into their current multiples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Lilly’s Zepbound in short supply at Amazon Pharmacy, Rite Aid, Bloomberg says
- Early notable gainers among liquid option names on March 28th
- Ozempic manufacturing costs could be 89c per month, study finds
- Viking (NASDAQ:VKTX): Positive Trial Data Boosts Stock
- Amgen shares worth $240-$250 without obesity pipeline, says JPMorgan